Yarrow Bioscience Updates Business Disclosure After Merger

What Happened

• Yarrow Bioscience, Inc. filed a Current Report on Form 8‑K on September 10, 2026 announcing it made an investor presentation available and updated Part I, Item 1 — Business of its Form 10‑K for the year ended December 31, 2025 to reflect the merger between the Company and Yarrow Bioscience Operating Company Corp. (formerly known as Yarrow Bioscience, Inc.).
• The updated business disclosure is filed as Exhibit 99.2 and the investor presentation as Exhibit 99.1 to the 8‑K. The filing states these revisions do not affect the Company’s previously reported results of operations, financial position, or cash flows.

Key Details

• Filing date: September 10, 2026 (Form 8‑K).
• Update: Part I, Item 1 — Business of the 2025 Form 10‑K revised to reflect the merger between the Company and Yarrow Bioscience Operating Company Corp.
• Exhibits: Investor presentation (Exhibit 99.1) and the business-update text (Exhibit 99.2) were filed and incorporated by reference.
• The company notes all other items in the 2025 10‑K remain unchanged and revisions do not alter previously reported financials.

Why It Matters

• This is primarily a disclosure update to reflect a corporate merger and the related business description; it is not a report of earnings, leadership change, or a change to historical financial results.
• Retail investors should view this as a corporate-structure/business-description update and refer to future Form 10‑Q and 8‑K filings for any material operational or financial developments after December 31, 2025. The filing also includes standard forward‑looking statements cautioning that outcomes may differ from current expectations.